Open Government Portal

Variant strains of SARS-CoV-2 are emerging that may affect the level of protection provided by currently authorized COVID-19 vaccines. As a result, manufacturers are adapting authorized COVID-19 vaccines to provide protection against infection and disease caused by virus variants.

The purpose of this document is to provide guidance to manufacturers of serological assays intended for the detection of antibodies to SARS-CoV-2, the virus that causes COVID-19 disease. The guidance outlines recommendations regarding the minimum testing that should be performed for SARS-CoV-2 diagnostics.

The Public Health Agency of Canada, in collaboration with provincial and territorial public health authorities, established the Canadian SARS-CoV-2 Variant Surveillance Group (CSVSG) to monitor and assess the impact of variants of SARS-CoV-2 on viral transmissibility, disease severity, and efficacy of vaccines, therapeutics, and diagnostics. The CSVSG has developed national definitions, classifications, and public health actions for SARS-CoV-2 Variants of Interest (VOI) and Variants of Concern (VOC).

Health Canada has developed the following list of hard-surface disinfectants that are likely to be effective and may be used against SARS-CoV-2, the coronavirus that causes COVID-19. For these products, evidence was submitted demonstrating that they are effective against harder-to-kill viruses or other viruses very similar to SARS-CoV-2. This list is updated regularly.

As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. This dataset details the percentage of COVID-19 positive patients in hospitals and ICUs for COVID-19 related reasons, and for reasons other than COVID-19. Data includes: * reporting date * percentage of COVID-19 positive patients in hospital admitted for COVID-19 * percentage of COVID-19 positive patients in hospital admitted for other reasons * percentage of COVID-19 positive patients in ICU admitted for COVID-19 * percentage of COVID-19 positive patients in ICU admitted for other reasons Due to incomplete weekend and holiday reporting, data for hospital and ICU admissions are not updated on Sundays, Mondays and the day after holidays. This dataset is subject to change.

This document provides guidance to vaccine manufacturers seeking authorization for their vaccine that targets the SARS-CoV-2 virus. This guidance applies to applications under the interim order respecting the importation, sale and advertising of drugs for use in relation to COVID-19.

When people still show symptoms of COVID-19 for weeks or months after their initial recovery, it’s called post COVID-19 condition. It’s also known as long COVID. Post COVID-19 condition may occur in some people after infection.

The purpose of this document is to assist in planning immunization clinics for COVID-19 vaccines during the COVID-19 pandemic.

COVID-19 is a new disease not previously identified in humans. Currently there is no vaccine or therapeutic product for COVID-19 that is authorized to treat or prevent the disease. The outbreak of COVID-19 has resulted in a global review of therapies that could be used to treat or prevent the infection. In an effort to facilitate earlier access to a vaccine, or therapeutic product for COVID-19, the Department will expedite the review of any COVID-19 related health product submissions and applications.

The World Health Organization (WHO) refers to symptoms lasting for weeks or months after a COVID-19 infection as post COVID-19 condition. Some studies have reported later symptoms in patients with a severe COVID-19 infection. For example, those who were hospitalized or needed intensive care during recovery. However, post COVID-19 condition may also occur for people with mild or asymptomatic infection who were asked to isolate at home during the infectious phase.